|
- Study Details | Multi-centers, Open-Label, Phase 2 Study to Evaluate . . .
This is a multi-centers, single-arm, open label, Phase 2 clinical trial to evaluate the efficacy and safety of CD7 CAR T cells in subjects with relapsed or refractory T-cell leukemia lymphoma Seventy subjects will be enrolled
- Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r r T-Cell . . .
The phase 2 trial was using Bayesian optimal phase 2 (BOP2) design to evaluate the efficacy and safety of the target dose of 1 × 10 6 (±20%) CD7 CAR T cells per kg of body weight in refractory relapsed T-cell acute lymphoblastic leukemia lymphoma (NCT04689659)
- Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute . . .
Among 20 patients with r r T-ALL enrolled in this trial, donor-derived CD7 CAR T cells exhibited efficient expansion and achieved a high complete remission rate with manageable safety profile A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress (NCT04689659)
- Trial | NCT04689659
This is a multi-centers, single-arm, open label, Phase 2 clinical trial to evaluate the efficacy and safety of CD7 CAR T cells in subjects with relapsed or refractory T-cell leukemia lymphoma Seventy subjects will be enrolled CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells
- Targeted CD7 CAR T-cells for treatment of T-Lymphocyte leukemia and . . .
At the 2022 ASH, the PAN team presented an interim report from the Phase II clinical trial of donor-derived CD7 CAR T-cells for the treatment of R R T-cell acute lymphoblastic leukemia lymphoma (NCT04689659) (68)
- Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and . . .
This is a multi-centers, single-arm, open label, Phase 2 clinical trial to evaluate the efficacy and safety of CD7 CAR T cells in subjects with relapsed or refractory T-cell leukemia lymphoma Seventy subjects will be enrolled CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells
- Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute . . .
Among 20 patients with r r T-ALL enrolled in this trial, donor-derived CD7 CAR T cells exhibited efficient expansion and achieved a high complete remission rate with manageable safety profile A multicenter, phase II trial of donor-derived CD7 CAR T cells is in progress (NCT04689659)
- Chimeric antigen receptor T cell treatment in Relapse . . . - ICH GCP
Clinical Trial NCT04689659 Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia Lymphoma
|
|
|